Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging

Fibroblast activation protein (FAP) is regarded as a promising target for the diagnosis and treatment of tumors as it was overexpressed in cancer-associated fibroblasts. FAP inhibitors bearing a quinoline scaffold have been proven to show high affinity against FAP in vitro and in vivo, and the scaffold has been radio-labeled for the imaging and treatment of FAP-positive tumors. However, currently available FAP imaging agents both contain chelator groups to enable radio-metal labeling, making those tracers more hydrophilic and not suitable for the imaging of lesions in the brain. Herein, we report the synthesis, radio-labeling, and evaluation of a 18F-labeled quinoline analogue ([18F]3) as a potential FAP-targeted PET tracer, which holds the potential to be blood–brain barrier-permeable. [18F]3 was obtained by one-step radio-synthesis via a copper-mediated SNAR reaction from a corresponding boronic ester precursor. [18F]3 showed moderate lipophilicity with a log D 7.4 value of 1.11. In cell experiments, [18F]3 showed selective accumulation in A549-FAP and U87 cell lines and can be effectively blocked by the pre-treatment of a cold reference standard. Biodistribution studies indicated that [18F]3 was mainly excreted by hepatic clearance and urinary excretion, and it may be due to its moderate lipophilicity. In vivo PET imaging studies indicated [18F]3 showed selective accumulation in FAP-positive tumors, and specific binding was confirmed by blocking studies. However, low brain uptake was observed in biodistribution and PET imaging studies. Although our preliminary data indicated that [18F]3 holds the potential to be developed as a blood–brain barrier penetrable FAP-targeted PET tracer, its low brain uptake limits its application in the detection of brain lesions. Herein, we report the synthesis and evaluation of [18F]3 as a novel small-molecule FAPI-targeted PET tracer, and our results suggest further structural optimizations would be needed to develop a BBB-permeable PET tracer with this scaffold.

[1]  G. Huang,et al.  Radiosynthesis and First Preclinical Evaluation of the Novel 11C-Labeled FAP Inhibitor 11C-FAPI: A Comparative Study of 11C-FAPIs and (68Ga) Ga-DOTA-FAPI-04 in a High–FAP-Expression Mouse Model , 2022, Frontiers in Chemistry.

[2]  Jinming Yu,et al.  [18F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  F. Gao,et al.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors , 2022, Frontiers in Oncology.

[4]  T. Lan,et al.  Synthesis and Preliminary Evaluation of 131I-Labeled FAPI Tracers for Cancer Theranostics. , 2021, Molecular pharmaceutics.

[5]  J. Debus,et al.  Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET/CT in cancer patients , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Aiping Lu,et al.  ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties , 2021, Nucleic Acids Res..

[7]  Shiming Ye,et al.  Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts , 2021, Acta pharmaceutica Sinica. B.

[8]  Shaobo Yao,et al.  Primary Central Nervous System Lymphoma Revealed by 68Ga-FAPI and 18F-FDG PET/CT. , 2021, Clinical nuclear medicine.

[9]  M. Yadav,et al.  Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Guillermo A. Gomez,et al.  Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy , 2020, Clinical & translational immunology.

[11]  U. Haberkorn,et al.  Targeting of activated fibroblasts for imaging and therapy , 2019, EJNMMI Radiopharmacy and Chemistry.

[12]  Yiyun Huang,et al.  Synthesis and in Vivo Evaluation of a Novel PET Radiotracer for Imaging of Synaptic Vesicle Glycoprotein 2A (SV2A) in Nonhuman Primates. , 2018, ACS chemical neuroscience.

[13]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[14]  Dong-Sheng Cao,et al.  ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database , 2018, Journal of Cheminformatics.

[15]  P. Gascard,et al.  Carcinoma-associated fibroblasts: orchestrating the composition of malignancy , 2016, Genes & development.

[16]  D. Jäger,et al.  Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro. , 2015, Advances in medical sciences.

[17]  E. Puré,et al.  Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. , 2015, Cancer research.

[18]  J. Passchier,et al.  A general copper-mediated nucleophilic 18F fluorination of arenes. , 2014, Angewandte Chemie.

[19]  O. Schilling,et al.  Understanding fibroblast activation protein (FAP): Substrates, activities, expression and targeting for cancer therapy , 2014, Proteomics. Clinical applications.

[20]  A. Lambeir,et al.  Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). , 2014, Journal of medicinal chemistry.

[21]  E. Puré,et al.  Targeting Fibroblast Activation Protein in Tumor Stroma with Chimeric Antigen Receptor T Cells Can Inhibit Tumor Growth and Augment Host Immunity without Severe Toxicity , 2013, Cancer Immunology Research.

[22]  L. Chen,et al.  Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand. , 2013, Journal of medicinal chemistry.

[23]  J. Lai,et al.  Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. , 2013, Journal of medicinal chemistry.

[24]  A. Lambeir,et al.  Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold. , 2013, ACS medicinal chemistry letters.

[25]  Yuan Zhang,et al.  Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. , 2011, Cancer letters.

[26]  Jia Fan,et al.  Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. , 2009, American journal of clinical pathology.

[27]  L. Weiner,et al.  Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma , 2008, Pancreas.

[28]  K. Heider,et al.  Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts , 2008, Clinical Cancer Research.

[29]  E. Ross,et al.  Clinical Implications of Fibroblast Activation Protein in Patients with Colon Cancer , 2007, Clinical Cancer Research.

[30]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[31]  E. Gilboa,et al.  Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. , 2005, Cancer research.

[32]  S. Larson,et al.  A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  D. Jäger,et al.  Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer , 2003, Oncology Research and Treatment.

[34]  J. Healey,et al.  Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Scott,et al.  Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.